Technical Analysis for LQDA - Liquidia Technologies, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Earnings Movers | Other | 3.99% | |
Inside Day | Range Contraction | 3.99% | |
Lower Bollinger Band Touch | Weakness | 3.99% | |
New Downtrend | Bearish | 6.86% | |
Reversal New Lows Setup | Bearish Swing Setup | 6.86% | |
Doji - Bullish? | Reversal | 6.86% | |
Stochastic Reached Oversold | Weakness | 6.86% | |
Earnings Movers | Other | 6.86% | |
Outside Day | Range Expansion | 6.86% | |
Gapped Down | Weakness | 6.86% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | 11 minutes ago |
20 DMA Resistance | about 1 hour ago |
Rose Above 20 DMA | about 1 hour ago |
Up 3% | about 1 hour ago |
Up 2% | about 2 hours ago |
Get a Trading Assistant
- Earnings date: 05/14/2024
Liquidia Technologies, Inc. Description
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pain Medication Hypertension Clinical Trial Opioids Pulmonary Arterial Hypertension Uniform Bupivacaine Inhaler Treprostinil
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.99 |
52 Week Low | 5.71 |
Average Volume | 856,420 |
200-Day Moving Average | 10.24 |
50-Day Moving Average | 14.05 |
20-Day Moving Average | 12.69 |
10-Day Moving Average | 12.47 |
Average True Range | 0.62 |
RSI (14) | 38.65 |
ADX | 26.57 |
+DI | 10.61 |
-DI | 26.65 |
Chandelier Exit (Long, 3 ATRs) | 12.39 |
Chandelier Exit (Short, 3 ATRs) | 13.50 |
Upper Bollinger Bands | 13.59 |
Lower Bollinger Band | 11.80 |
Percent B (%b) | 0.27 |
BandWidth | 14.03 |
MACD Line | -0.52 |
MACD Signal Line | -0.52 |
MACD Histogram | -0.0042 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.28 | ||||
Resistance 3 (R3) | 13.19 | 12.78 | 13.12 | ||
Resistance 2 (R2) | 12.78 | 12.52 | 12.82 | 13.06 | |
Resistance 1 (R1) | 12.53 | 12.37 | 12.66 | 12.62 | 13.00 |
Pivot Point | 12.12 | 12.12 | 12.18 | 12.16 | 12.12 |
Support 1 (S1) | 11.87 | 11.86 | 12.00 | 11.96 | 11.58 |
Support 2 (S2) | 11.46 | 11.71 | 11.50 | 11.52 | |
Support 3 (S3) | 11.21 | 11.46 | 11.47 | ||
Support 4 (S4) | 11.30 |